Supportive Care in Cancer 2020-May
Letter Referencing "Randomized Open-Label Phase II Trial of 5-day Aprepitant Plus Ondansetron Compared to Ondansetron Alone in the Prevention of Chemotherapy-Induced Nausea-Vomiting in Glioma Patients Receiving Adjuvant Temozolomide"
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Link salvestatakse lõikelauale